Paclitaxel albumin bound is under clinical development by Bristol-Myers Squibb and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel albumin bound’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel albumin bound overview
Paclitaxel (Abraxane, Abraxus ABI-007) is a taxane derivative, acts as anti-neo plastic agent. It is formulated as a lyophilized powder for suspension for the intravenous route of administration. Abraxane is indicated for the treatment of metastatic breast cancer, after the failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy, metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
It is under development for the treatment of metastatic adenocarcinoma of the esophagus, GE junction, or stomach who progressed on one prior line of chemotherapy, solid tumor, soft tissue sarcoma, gallbladder cancer, metastatic biliary tract cancer, colorectal cancer, metastatic pancreatic ductal adenocarcinoma, operable oesogastric adenocarcinoma, advanced urothelial cancer, gastrointestinal tract cancer, Bile Duct Cancer (Cholangiocarcinoma).
It was also under development for ovarian cancer, bladder cancer, restenosis, squamous cell carcinoma, metastatic melanoma. It was also under development for as a second line therapy for transitional cell cancer (urothelial cell cancer), cancer of unknown primary (CUP), epithelial ovarian cancer, fallopian tube cancer, metastatic triple negative breast cancer, peritoneal cancer, pancreatic cancer, urothelial carcinoma, nasopharyngeal carcinoma, cervical carcinoma, anal carcinoma, pancreatic cancer (adjuvant therapy), lung adenocarcinoma (second line therapy) and Merkel cell carcinoma (MCC), squamous cell non-small cell lung cancer, HER2 positive breast cancer, small cell lung cancer, Ewing's sarcoma, neuroblastoma and rhabdomyosarcoma.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Paclitaxel albumin bound’s drug-specific PTSR and LoA scores, buy the report here.